{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76","upperLimit":"91","value":"85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Assessed using Kaplan Meier and Proportional Hazards","dispersionType":"95% Confidence Interval","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.\n\nfludarabine phosphate: Given IV\n\nmelphalan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\ntacrolimus: Given IV or PO\n\nmycophenolate mofetil: Given IV or PO\n\nmethotrexate: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo PBSCT","id":"OG000","title":"Treatment (Reduced Intensity Allogeneic PBSCT)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"day of transplant until progression up to 5 years","title":"Progression Free Survival (PFS) at One Year","type":"SECONDARY","unitOfMeasure":"percentage of participants"}